Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Nektar Therapeutics (NASDAQ: NKTR) closed at $0.90 down -2.99% from its previous closing price of $0.93. In other words, the price has decreased by -$2.99 from its previous closing price. On the day, 1.71 million shares were traded. NKTR stock price reached its highest trading level at $0.9245 during the session, while it also had its lowest trading level at $0.8701.
Ratios:
For a deeper understanding of Nektar Therapeutics’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.24 and its Current Ratio is at 4.24. In the meantime, Its Debt-to-Equity ratio is 4.22 whereas as Long-Term Debt/Eq ratio is at 3.78.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 10, 2024, initiated with a Buy rating and assigned the stock a target price of $6.50.
On November 04, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $7.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 23 ’24 when Wilson Mark Andrew bought 33,402 shares for $0.90 per share.
Zalevsky Jonathan sold 51,115 shares of NKTR for $48,048 on Dec 19 ’24. The Chief R&D Officer now owns 326,904 shares after completing the transaction at $0.94 per share. On Dec 18 ’24, another insider, ROBIN HOWARD W, who serves as the President & CEO of the company, sold 85,035 shares for $0.99 each. As a result, the insider received 84,185 and left with 1,110,675 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 166104432 and an Enterprise Value of 132828624. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.76 while its Price-to-Book (P/B) ratio in mrq is 3.40. Its current Enterprise Value per Revenue stands at 1.426 whereas that against EBITDA is -1.02.
Stock Price History:
Over the past 52 weeks, NKTR has reached a high of $1.93, while it has fallen to a 52-week low of $0.46. The 50-Day Moving Average of the stock is -23.41%, while the 200-Day Moving Average is calculated to be -28.73%.
Shares Statistics:
For the past three months, NKTR has traded an average of 1.75M shares per day and 1666110 over the past ten days. A total of 184.46M shares are outstanding, with a floating share count of 177.51M. Insiders hold about 3.77% of the company’s shares, while institutions hold 74.38% stake in the company. Shares short for NKTR as of 1732838400 were 4440183 with a Short Ratio of 2.54, compared to 1730332800 on 5226179. Therefore, it implies a Short% of Shares Outstanding of 4440183 and a Short% of Float of 3.08.
